The degree of lineage commitment of the hematopoietic stem cell in chronic myelomonocytic leukemia (CMML) and in acute myelogenous leukemia (AML) remains debatable and may be heterogeneous depending on the patient subgroup. In this study, we have used a modification of DNA in situ hybridization which adapts this technique to the analysis of karyotype in single hematopoietic colonies. By utilizing a digoxigenin-labeled chromosome 7 probe, we demonstrate that, in patients with monosomy 7, both erythroid and myelomonocytic progenitors can be karyotypically aberrant. In addition, significant levels of diploid clonogenic cells persist (as reflected by the presence of between 14% and 43% diploid colonies) despite the detection of only monosomy 7-bearing bone marrow metaphases as assessed by standard cytogenetic techniques. Our observations demonstrate that digoxigenin-based DNA in situ hybridization (DISH) can be performed on individually microaspirated colonies for determination of lineage derivation. This technique may also be applicable to the detection of minimal residual disease with clonogenic potential and for assessing the interaction between normal and leukemic precursors.
Introduction
Both acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) are well-established as clonal disorders originating in a single stem cell. [1] [2] [3] [4] The degree of lineage commitment of this cell remains unclear. In MDS, the frequent development of pancytopenia may be taken as an implication that a multipotent progenitor is involved. This phenomenon could however also occur in a disease originating in a lineagecommitted progenitor if a suppressive factor was secreted by the neoplastic cell. A variety of molecular techniques have been used to determine the level of differentiation of the MDS and AML stem cell with equivocal results. For instance, using polymerase chain reaction (PCR) to detect X-chromosome inactivation patterns in erythroid and nonerythroid colonies, Asano et al 5 demonstrated involvement of a progenitor capable of differentiating into the erythroid or the myelomonocytic lineage in patients with the refractory anemia (RA) or RA with excess blasts (RAEB) subtypes of MDS. By combining surface labeling and fluorescent in situ hybridization (FISH), Kibbelaar et al 6 found that in four MDS patients (RAEB, RAEB in transformation (RAEBT), or unclassified hypoplastic MDS) with trisomy 8, CD34-positive cells expressed trisomy 8 whereas lymphocytes did not. Since CD34 is a marker of early hemopoietic cells, these results suggested that the clonal abnormality occurs in a progenitor cell but that this cell is committed to myeloid differentiation, and the very early stem cell is not affected. However, studies utilizing restriction fragment length polymorphisms (RFLPs) or other methods have shown a monoclonal expression pattern in T-and B-lymphocytes in some patients with MDS but not in others. 1, 3, [7] [8] [9] [10] In AML, Keinan and coworkers 11 observed that two of four patients with trisomy 8 had normal erythrocytic cells whereas in the other two patients this lineage was affected. Heterogeneity in erythrocytic and megakaryocytic involvement has also been demonstrated by other investigators. 4, [11] [12] [13] [14] [15] Taken together these results indicate that the degree of lineage commitment of the neoplastic stem cell in MDS and AML remains a matter of debate, and may differ in various patient subsets. Further, to date, few patients with CMML have been examined. We use a new modification of DNA in situ hybridization technology in which this method is adapted for performance on single colonies to determine lineage derivation in patients with CMML or AML and monosomy 7. In contrast to FISH analysis of blood or bone marrow or to RFLP analysis, this technique examines cells with proliferative capacity. It may therefore also be applicable to the detection of residual leukemia in disease-sustaining progenitors and for assessment of the interaction between neoplastic and normal colonies.
Materials and methods
After informed consent was obtained in accordance with the recommendations of our Institutional Review Board, bone marrow cells were collected by iliac crest aspiration. Whole single colonies were then grown in the colony-forming unit granulocytes-erythroid-macrophage-megakaryocyte (CFU-GEMM) assay (see below) and microaspirated on to poly-llysine-treated glass slides (Sigma, St Louis, MO, USA). They were then dried, wrapped in plastic, and placed in −20°C until use. In order to isolate single cells from colonies, in some cases, colonies were plucked into phosphate-buffered saline (PBS) and single colonies were then cytospun on to the poly-l-lysine-treated slides. In situ hybridization of individual colonies was per-formed with digoxigenin-labeled chromosome 7 probe D7Z1,2 (Oncor, Gaithersburg, MD, USA).
CFU-GEMM assay
The CFU-GEMM assay is performed according to Fauser and Messner. 16 In brief, 2 × 10 5 nucleated non-adherent cells are cultured in methylcellulose with Iscove's modified Dulbecco's medium (Gibco, Grand Island, NY, USA), 30% FCS (Flow, McLean, VA, USA), 2% leukocyte-conditioned medium prepared with phytohemagglutinin (PHA-LCM), GM-CSF 5-15 ng/ml and human erythropoietin 1.0 U/ml (British Columbia Cancer Research Institute, Vancouver, Canada). One milliliter of the culture mixture is placed in 35-mm Petri dishes (LUX; Nunc, Naperville, IL, USA) and incubated at 37°C with 5% CO 2 in air in a humidified atmosphere. All cultures were evaluated after 14 days for the number of burst forming uniterythroid (BFU-E) colonies (defined as an aggregate of 500 hemoglobinized cells or three or more erythroid subcolonies), CFU-GM colonies of granulocytic or monocyte-macrophage cells or both, and mixed colonies containing all elements.
Digoxigenin-based DNA in situ hybridization (DISH) DISH for the presence of chromosome 7 was performed according to the method recommended by the manufacturer of the chromosome 7 probe D7Z1,2 (Oncor). The reagents and solutions used were provided in a hybridization kit (Oncor).
The method involves slide denaturation by immersing the slides in 40 ml of prewarmed denaturation solution (70% formamide/2 × SSPE (sodium chloride, sodium phosphate, EDTA) adjusted to pH 7.0 with concentrated hydrochloride) in a glass coplin jar warmed to 70°C in a water bath. The slides are then dehydrated successively in cold (−20°C) 70%, 80%, and 95% ethanol for 2 min each. Probe is prepared by pre-warming at 37°C for 5 min. The probe is then vortexed gently and centrifuged 2-3 s to collect contents in the bottom of the tube. 1.5 l of probe is then combined with 30 l of Oncor Hybrisol VI in a microcentrifuge tube and vortexed gently to mix. The probe solution is denatured by heating in a 70°C water bath for 5 min and then centrifuging for 2-3 s to collect contents in the bottom of the tube. The probe is placed in a 4°C ice bath until ready to hybridize. Hybridization is performed by placing 20 l of probe solution on each slide and covering with a 22 × 5 mm glass coverslip. The perimeter of the glass coverslip is sealed to the slide with a thick layer of rubber cement. The slides are incubated at 37°C in a pre-warmed humidified chamber for 2.5 h. A post-hybridization wash is performed by prewarming 40 ml of appropriate SSPE wash solution in a glass coplin jar to 72°C in a water bath, carefully removing the rubber cement with forceps, and then gently lifting the coverslip off the slide, followed by immersing the slides in prewarmed SSPE wash solution for 5 min. The slides are then transferred to a coplin jar containing 40 ml of 1 × PBD (Oncor) for 2 min.
Detection is performed by removing the slides, then incubating with 60 l of HRP/anti-digoxigenin for 30 min at 37°C in a humidified chamber. The slides are then washed three times in 1 × PBD for 2 min each wash. Enzymatic counterstaining is then done by applying 2 ml of Wright stain solution to each slide and incubating at room temperature for 5 min. The staining solution is flushed from the slide using a stream of distilled water from a squirt bottle. The slides are then dipped into a coplin jar containing xylene. After removing the slides from the xylene, 1-2 drops of the mounting medium is placed on the slide. Afterwards the slides are covered with a glass coverslip and viewed using a light microscope.
Cytogenetic studies
Cytogenetic analysis was performed on bone marrow samples cultured overnight without mitogenic stimulation in Ham's F10 medium with 10% fetal calf serum. Standard Giemsa staining which yielded G-banded chromosomes was performed on slides after a trypsin treatment.
Results
Samples from three patients were analyzed (Table 1) . In two cases, the patients were diagnosed as having CMML; the third patient had AML. The criteria for diagnosis of CMML were in accordance with those described by Bennett et al 17 and included an absolute monocytosis (Ͼ1 × 10 9 /l), with less than 20% bone marrow blasts. AML was diagnosed in the presence of over 30% myeloperoxidase-positive blasts. The two patients with CMML (cases 1 and 2) were newly diagnosed whereas the patient with AML had relapsed disease ( Table 1 ). Both of the CMML patients had had previous hematologic malignancies (multiple myeloma and chronic lymphocytic leuke- mia, respectively) which had been treated with chemotherapy and were in remission at the time of development of CMML. A total of 14, 16 and 14 colonies were analyzed on patients 1, 2 and 3, respectively (Table 2) . Representative colonies are displayed in Figure 1 . Cytocentrifugation of single colonies resulted in distortion of colony architecture and cellular morphology. Nevertheless details of nuclear morphology were well preserved (Figure 1) . The colonies were evenly divided between CFU-GMs and BFU-Es. In each case, colonies with two chromosomes 7 in each cell and colonies with monosomy 7 coexisted (Table 2) . Between 56% (case 2) and 86% (case 3) of the colonies had monosomy 7. However, as expected, the vast majority of the cells within any one colony were identical with respect to the number of chromosome 7 signals seen. The false-positive rate (detection of cells with a single chromosome 7 signal in a diploid colony) was 5%; the false-negative rate (detection of two chromosome 7 signals in a monosomy 7 colony) was 2%. The false-positive and falsenegative rate was determined by counting all the cells in all the colonies evaluated.
Discussion
In this study, we apply a novel technique using digoxigeninlabeled probes and DNA in situ hybridization (DISH) to determine the number of chromosomes 7 present in individually plucked colonies from CMML and AML patients with monosomy 7. Since all the cells in any one colony are derived from a single precursor, they should all have the same karyotype. Therefore, determination of the karyotype of a colony is straightforward and would remain unaffected by the 5% rate of loss of signals or the 2% rate of extra signals observed with this technique (false-positives or -negatives). In contrast, the presence of even a small number of false-negatives or -positives when in situ hybridization is applied to sorted populations of cells could conceivably confound the interpretation of the results by suggesting the possible existence of diploid cells amongst the malignant population or the existence of malignant cells amongst the diploid population. In addition, since this technique examines clonogenic cells capable of repopulating the bone marrow, it may be useful in discerning the presence of minimal residual disease. Indeed, we have previously shown that, with the use of PCR to detect the BCR-ABL molecular anomaly in individual colonies from Philadelphia chromosome-positive chronic myelogenous leukemia (CML) patients in complete cytogenetic remission, residual disease can be found even in individuals whose whole blood or bone marrow samples are PCR-negative. 18 Whether a very primitive pluripotent hematopoietic stem cell or a more committed descendant is involved in MDS and AML remains controversial. Probably the degree of lineage commitment of the stem cell varies depending on the subgroup of patients examined. The loss of all or part of chromosome 7 is one of the most frequent chromosome abnormalities discerned in MDS, occurring in 5 to 30% (20% in CMML) of patients with an abnormal karyotype. 19, 20 In both CMML and AML, it is associated with a poor response rate and short survival. 19, 21 Even so, although several groups have examined lineage involvement in MDS and AML, only a small number of patients with monosomy 7 and even fewer with CMML have been analyzed. In 19 of a total of 20 non-CMML patients with MDS and monosomy 7, several investigators [22] [23] [24] showed involvement of the myeloid, but not of the lymphoid, lineage with the use of FISH and EBV transformed B cells, or FISH and cell sorting of lymphoid and myeloid lineages. One patient also showed lymphoid lineage involvement. Kibbelaar et al 6 found similar results using the same type of approach in a patient with RAEB and a −7, +t(1;7) anomaly. Using RFLP analysis, lack of involvement of the lymphoid lineage has also been reported in a total of six patients 25, 26 with MDS (RA or RAEB) and chromosome 7 anomalies. To our knowledge, only one case of CMML with a chromosome 7 anomaly has been analyzed. In this case, 27 the 7q− marker was detected in CFUGMs and BFU-Es, but not in EBV-transformed lymphocytes. In contrast, using X-linked clonality tests, Culligan and colleagues 8 demonstrated monoclonal lymphocytes in three of six diploid CMML samples and Janssen et al 28 showed that a mutated RAS oncogene can be found by PCR in the lymphocytes, as well as the granulocytes and monocytes derived from two individuals with CMML (but without chromosome 7 aberrations). 28 The discrepancy in these results suggesting the origin of CMML in a partially committed progenitor cell 27 vs an early pluripotent precursor 28 might be attributable to: (1) minor contamination of cell populations in the PCR-based study; 28 (2) a multistep process with the proliferation of a clone of pluripotent cells followed by the development of a karyotypic abnormality in a lineage-committed descendant of this clone; 29 or (3) to heterogeneity in lineage derivation amongst CMML patients. Similar heterogeneity in origin has been previously demonstrated in Philadelphia chromosomepositive acute lymphoblastic leukemia, with involvement of either a pluripotent precursor or a lymphoid lineage-committed hematopoietic progenitor. 30 In AML with monosomy 7, Keinan and coworkers 11 showed that cells of granulocyticmonocytic and erythrocytic lineage (four cases) and megakaryocytic lineage (one case) had the monosomy 7 karyotype (as assessed by cytogenetic procedures), while Kere et al 25 found that the lymphocytes were diploid in the one patient analyzed.
Our experiments demonstrate that both BFU-E and CFU-GM colonies in CMML and AML patients with monosomy 7 can be karyotypically aberrant (Table 2 ). This observation supports the involvement of both the erythroid and myeloid lineage in these patients. Of interest, in all three cases, diploid colonies (range, 14 to 43%) were present, despite the observation of only monosomy 7 bearing metaphases in cases 2 and 3 by standard bone marrow cytogenetics. The latter findings suggests that significant levels of karyotypically normal hematopoiesis persists in these patients implying either incomplete or absent suppression of diploid cell proliferation by the clone with monosomy 7. (The discrepancy between standard karyotype results and the clonogenic assay may be due to differing culture conditions.) Similar findings have been reported in acute lymphoblastic leukemia as well. 31 Finally, our studies indicate that the use of DNA in situ hybridization on individually microaspirated colonies is a simple technique for the elucidation of lineage derivation. It may also be applicable to assessing minimal residual disease in bone marrow-derived clonogenic cells with proliferative capacity.
